Allergy Therapeutics plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AGYTF research report →
Price Chart
About the company
Allergy Therapeutics plc is a biotechnology firm dedicated to the research, development, and commercialization of innovative treatments for allergic conditions. The company offers a variety of allergen-specific immunotherapies, available as both injectable solutions and sublingual (under-the-tongue) formulations. Their product line includes prescription medications specifically designed to address pollen-related allergies, such as those caused by grasses, weeds, and trees, along with various diagnostic tools.
- CEO
- Manuel Llobet
- IPO
- 2010
- Employees
- 612
- HQ
- Worthing, WSX, GB
Get TickerSpark's AI analysis on AGYTF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $756.30M
- P/E
- -4.55
- Fwd P/E
- 12.28
- PEG
- 0.32
- P/S
- 4.97
- P/B
- 55.33
- EV/EBITDA
- -9.22
- Div Yield
- 0.00%
- Gross Margin
- 41.17%
- Op Margin
- -60.23%
- Net Margin
- -85.46%
- ROE
- 409.00%
- ROIC
- -84.29%
Latest fiscal year · YoY change
- Revenue
- $75.56M+36.9%
- Gross Profit
- $34.50M+16.0%
- Op Income
- $-28,162,000
- Net Income
- $-55,093,209-37.0%
- EPS
- $-0.01+21.5%
- OCF Growth
- -22.7%
- FCF Growth
- -23.5%
- 52W High
- $0.15
- 52W Low
- $0.09
- 50D MA
- $0.15
- 200D MA
- $0.13
- Beta
- 0.83
- RSI (14)
- 100
- Avg Volume
- 5.44K
No earnings-call transcripts are available for AGYTF yet.
- Free Float
- 6.6%
- Shares Outstanding
- 5.04B
- Float Shares
- 331.58M
Our AGYTF coverage
Recent articles, reports, and earnings notes.
No research on AGYTF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AGYTF report →Boston Scientific beats second quarter expectations, raises full-year outlook
proactiveinvestors.com · Jul 29
Allergy Therapeutics reports accelerated revenue growth in its second half
proactiveinvestors.com · Jul 29
Allergy Therapeutics reports accelerated revenue growth in its second half
proactiveinvestors.co.uk · Jul 29
Allergy Therapeutics names Helge Weiner-Trapness as executive chair
proactiveinvestors.com · Jul 28
Allergy Therapeutics names Helge Weiner-Trapness as executive chair
proactiveinvestors.co.uk · Jul 28
FTSE 100 Live: London stocks surge, Wall St volatile as SpaceX trading nears
proactiveinvestors.com · Jun 12
Allergy Therapeutics to showcase pollen and food allergy progress
proactiveinvestors.co.uk · Jun 12
Allergy Therapeutics to showcase pollen and food allergy progress
proactiveinvestors.com · Jun 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.